Avid Bioservices Inc (CDMO)

[RRdog]

To All,

What has taken a back seat in all the sturm und drang of negative posting and stock volatility is that the MOS in 2nd line NSCLC trial has still not evented and therefor is extending into the ESMO conference.

If MOS has not evented by ESMO, IMO it will be at approx 14 mo - 15.5 mos for the high dose bavi treatment arm. The range depends on how much time in advance the numbers were cut off before being finalized for the Chicago Symposium.

I also note that dosage does matter a bit contrary to some opinion. By pooling the arms PPHM may have gotten slightly better stat results and ratios but the higher dosage was running about 12-16% better than the low dosage arm at the cutoff date for Chicago Symposium.

If Garnick chooses to use only the higher 3mg dosage in the Phase III trial the results might have an edge over the Phase II data to the extent that dosage matters. This possibility will not be lost on either the scientists or potential partners IMO. IMO PPHM will also make it clear to partners that PPHM wants to extend clinicals into the area of combo with irradiation where more PS can be exposed and dosing may make even more of an impact.

Best Regards,
RRdog